STOCKHOLM, SWEDEN--(Marketwire - February 13, 2013) - Sobi (STO: Sobi) announced that it has
entered into a distribution agreement with PharmaSwiss to market the
products
Megace®, Monopril®, Cefzil® and Duricef® approved for
the treatment of
indications within the oncology, cardio-vascular and anti-infective therapy
areas. Under the terms of the agreement, Sobi will have distribution rights
in
Ireland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden,
Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal,
and
Luxembourg. All products are approved within the Sobi territory, where
sales in
2012 were approximately SEK 120 million (EUR 14 million). Sobi expects to
initiate distribution for the portfolio by the end of the first quarter
2013.

Anders Edvell, Vice President and Head of Partner Products at Sobi, said:
"We
have built a unique European platform with Partner Products to support the
complex clinical and reimbursement requirements of niche and specialty
products. We are delighted to be able to provide patients and physicians
with
this portfolio of important treatment options, and to welcome PharmaSwiss
as a
new partner."

About Megace® (megestrol): Megace is a progestogen hormone drug is
indicated
for the treatment of certain hormone-dependent neoplasms such as breast
cancer.

About Monopril® (fosinopril): Monopril is an angiotensin converting
enzyme
(ACE) inhibitor indicated for treatment of hypertension and congestive
heart
failure.

About Cefzil® (cefprozil): Cefzil is a broad-spectrum cephalosporin
antibiotic
indicated for the treatment of mild to moderate infections.

About Duricef® (cefadroxil): Duricef is a cephalosporin antibiotic
indicated
for the treatment of urinary tract infections, skin infections, pharyngitis
and/or tonsillitis, where the infections are caused by susceptible strains
of
designated microorganisms.

About Sobi Partner Products

Sobi Partner Products (SPP) is a business unit within Sobi which offers a
unique
commercial platform for partners with niche and specialty products. SPP
provides
extensive knowledge and local experience through our direct presence across
EU,
Eastern Europe, Russia, Middle East and North Africa. We apply an
integrated
commercial, medical, and market access approach to products which address
important unmet needs, working from named patient use (NPU) programs
through to
reimbursement and commercialization, primarily in the Centre of Expertise
setting. The key SPP therapeutic areas are Oncology, Hematology, Infectious
Diseases, and Emergency Medicines & Antidotes.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is
primarily
focused on inflammation and genetic diseases, with three late stage
biological
development projects within hemophilia and neonatology. We also market more
than
40 specialty and rare disease products for partner companies. Sobi is a
pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2011, Sobi had total revenues of SEK 1.9
billion (EUR
214 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ
OMX
Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information
was
released for public distribution on February 13, 2013 at 08:30 a.m. CET.